AI takes aim at 158-year-old eye exam

It may be time to take a long last look at the vision exam that relies on a cardboard sheet of huge letters at the top and tiny ones at the bottom.

That seemingly immortal element in every eye doctor’s office is known as the Snellen chart. It’s been around since 1862. But Snellen’s ingenuity is now being challenged, at least as a standalone, by an AI-based innovation that would take vision testing online.

The up-and-comer was recently developed at Stanford and is described in a study posted June 3 by Proceedings of the AAAI Conference on Artificial Intelligence.

In coverage of the research running in Science, reporter Marina Wang explains that the Stanford team ran its model through 1,000 computer simulations mimicking real patients. They found it reduced error by 74% compared with the Snellen test.

In the coverage, one ophthalmologist points out that online eye tests aren’t really new. Still, he allows, the use of AI for boosting accuracy is “clever.”

Another eye MD seems more impressed.

“I think that it would very quickly get adopted by over 80% of ophthalmology practices,” she says. “We really are desperate to have some good way of doing this.”

In any case, the plan is not to replace Snellen’s chart but to augment it.

Get the rest from Science:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.